Large numbers of people currently at risk for cardiovascular events are not receiving optimal therapy. Lowering the risk of CVD involves more than treatment of individual risk factors; it requires a comprehensive approach that augments the benefits of existing risk reduction therapies, as has been observed with the ACE inhibitors, including ramipril, captopril, lisinopril, and perindopril. Cardiovascular risk should be assessed early in order to reduce morbidity and mortality. Patients at high risk for cardiovascular morbidity and mortality are likely to benefit from administration of ACE inhibitors and statins. Additional outcomes trials using these agents in combination may be important in the future to determine if such combinations can produce additive or synergistic beneficial effects. Diabetic patients are among the patients at highest risk and are likely to benefit the most from early intervention with these classes of cardiovascular protective drugs.
|Translated title of the contribution||ACE inbitors and target organ protection|
|Number of pages||13|
|State||Published - Aug 2005|
ASJC Scopus subject areas